Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Mar;2(2):115-28.
doi: 10.1177/1756285608101861.

Natalizumab in the treatment of multiple sclerosis

Ozgür Yaldizli  1 , Norman Putzki
Affiliations

Natalizumab in the treatment of multiple sclerosis

Ozgür Yaldizli et al. Ther Adv Neurol Disord. 2009 Mar.

Abstract

Natalizumab reduced the rate of clinical relapse at one year by 68% and the risk of sustained progression of disability by 42-54% over 2 years in its pivotal phase III trial (AFFIRM) in relapsing-remitting multiple sclerosis (RRMS). Natalizumab is generally well tolerated, but due to rare and potentially fatal side-effects, it was approved with a restricted-distribution format in 2006. Expert statements and the European Medical Agency recommend the use of natalizumab after failure of first-line disease-modifying therapies in patients with relapsing forms of MS. As part of the risk management plan, worldwide extensive safety programmes aim to provide more data on natalizumab safety in clinical practice. At the end of September 2008, 48 000 patients have received natalizumab and 18000 patients are on treatment for at least 1 year. The assessment of risk and benefit is still ongoing.

Keywords: disease-modifying therapy; multiple sclerosis; natalizumab.

PubMed Disclaimer

References

    1. Astrom K.E., Mancall E.L., Richardson E.P., Jr(1958) Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and HJodgkin's disease, Brain 81: 93–111 - PubMed
    1. Bayless K.J., Meininger G.A., Scholtz J.M., Davis G.E.(1998) Osteopontin is a ligand for the alpha4beta1 integrin, J Cell Sci 111: 1165–1174 - PubMed
    1. Bernal-Cano F., Joseph J.T., Koralnik I.J.(2008) Spinal cord lesions of progressive multifocal encephalopathy in an acquired immunodeficiency syndrome patient, J Neurovirol 13: 474–476 - PubMed
    1. Bleyer W.A., Drake J.C., Chabner B.A.(1973) Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia, N Engl J Med 289: 770–773 - PubMed
    1. Bozic C., Belcher G., Kooijmans M., Kim R., Lynn F., Panzara M.A.(2007)The Safety of Natalizumab in Patients With Relapsing Multiple. Update from TOUCH(tm) and TYGRIS. Poster No P06.095, 59th Annual Meeting of the American Academy of Neurology, April 28 May 5, 2007 Boston, MA

LinkOut - more resources